BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 27542273)

  • 1. Sorafenib inhibits cell growth but fails to enhance radio- and chemosensitivity of glioblastoma cell lines.
    Riedel M; Struve N; Müller-Goebel J; Köcher S; Petersen C; Dikomey E; Rothkamm K; Kriegs M
    Oncotarget; 2016 Sep; 7(38):61988-61995. PubMed ID: 27542273
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of Autophagy by Chloroquine Enhances the Antitumor Efficacy of Sorafenib in Glioblastoma.
    Liu X; Sun K; Wang H; Dai Y
    Cell Mol Neurobiol; 2016 Oct; 36(7):1197-208. PubMed ID: 26971793
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sorafenib selectively depletes human glioblastoma tumor-initiating cells from primary cultures.
    Carra E; Barbieri F; Marubbi D; Pattarozzi A; Favoni RE; Florio T; Daga A
    Cell Cycle; 2013 Feb; 12(3):491-500. PubMed ID: 23324350
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sorafenib plus daily low-dose temozolomide for relapsed glioblastoma: a phase II study.
    Zustovich F; Landi L; Lombardi G; Porta C; Galli L; Fontana A; Amoroso D; Galli C; Andreuccetti M; Falcone A; Zagonel V
    Anticancer Res; 2013 Aug; 33(8):3487-94. PubMed ID: 23898124
    [TBL] [Abstract][Full Text] [Related]  

  • 5. EGFRvIII does not affect radiosensitivity with or without gefitinib treatment in glioblastoma cells.
    Struve N; Riedel M; Schulte A; Rieckmann T; Grob TJ; Gal A; Rothkamm K; Lamszus K; Petersen C; Dikomey E; Kriegs M
    Oncotarget; 2015 Oct; 6(32):33867-77. PubMed ID: 26418954
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of sorafenib on cisplatin-based chemoradiation in head and neck cancer cells.
    Möckelmann N; Rieckmann T; Busch CJ; Becker B; Gleißner L; Hoffer K; Omniczynski M; Steinmeister L; Laban S; Grénman R; Petersen C; Rothkamm K; Dikomey E; Knecht R; Kriegs M
    Oncotarget; 2016 Apr; 7(17):23542-51. PubMed ID: 27015558
    [TBL] [Abstract][Full Text] [Related]  

  • 7. NRAS mutations in cutaneous T cell lymphoma (CTCL) sensitize tumors towards treatment with the multikinase inhibitor Sorafenib.
    Kießling MK; Nicolay JP; Schlör T; Klemke CD; Süss D; Krammer PH; Gülow K
    Oncotarget; 2017 Jul; 8(28):45687-45697. PubMed ID: 28537899
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Concurrent radiotherapy and temozolomide followed by temozolomide and sorafenib in the first-line treatment of patients with glioblastoma multiforme.
    Hainsworth JD; Ervin T; Friedman E; Priego V; Murphy PB; Clark BL; Lamar RE
    Cancer; 2010 Aug; 116(15):3663-9. PubMed ID: 20564147
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Blockade of TGF-β signaling by the TGFβR-I kinase inhibitor LY2109761 enhances radiation response and prolongs survival in glioblastoma.
    Zhang M; Kleber S; Röhrich M; Timke C; Han N; Tuettenberg J; Martin-Villalba A; Debus J; Peschke P; Wirkner U; Lahn M; Huber PE
    Cancer Res; 2011 Dec; 71(23):7155-67. PubMed ID: 22006998
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synergistic anti-proliferative effect of metformin and sorafenib on growth of anaplastic thyroid cancer cells and their stem cells.
    Chen G; Nicula D; Renko K; Derwahl M
    Oncol Rep; 2015 Apr; 33(4):1994-2000. PubMed ID: 25683253
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The epidermal growth factor receptor pathway mediates resistance to sequential administration of radiation and chemotherapy in primary human glioblastoma cells in a RAS-dependent manner.
    Chakravarti A; Chakladar A; Delaney MA; Latham DE; Loeffler JS
    Cancer Res; 2002 Aug; 62(15):4307-15. PubMed ID: 12154034
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sorafenib inhibits intracellular signaling pathways and induces cell cycle arrest and cell death in thyroid carcinoma cells irrespective of histological origin or BRAF mutational status.
    Broecker-Preuss M; Müller S; Britten M; Worm K; Schmid KW; Mann K; Fuhrer D
    BMC Cancer; 2015 Mar; 15():184. PubMed ID: 25879531
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sorafenib exerts anti-glioma activity in vitro and in vivo.
    Siegelin MD; Raskett CM; Gilbert CA; Ross AH; Altieri DC
    Neurosci Lett; 2010 Jul; 478(3):165-70. PubMed ID: 20470863
    [TBL] [Abstract][Full Text] [Related]  

  • 14. NVP-BEZ235, a novel dual PI3K-mTOR inhibitor displays anti-glioma activity and reduces chemoresistance to temozolomide in human glioma cells.
    Yu Z; Xie G; Zhou G; Cheng Y; Zhang G; Yao G; Chen Y; Li Y; Zhao G
    Cancer Lett; 2015 Oct; 367(1):58-68. PubMed ID: 26188279
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dual mTORC1/2 blockade inhibits glioblastoma brain tumor initiating cells in vitro and in vivo and synergizes with temozolomide to increase orthotopic xenograft survival.
    Luchman HA; Stechishin OD; Nguyen SA; Lun XQ; Cairncross JG; Weiss S
    Clin Cancer Res; 2014 Nov; 20(22):5756-67. PubMed ID: 25316808
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differential radiosensitizing potential of temozolomide in MGMT promoter methylated glioblastoma multiforme cell lines.
    van Nifterik KA; van den Berg J; Stalpers LJ; Lafleur MV; Leenstra S; Slotman BJ; Hulsebos TJ; Sminia P
    Int J Radiat Oncol Biol Phys; 2007 Nov; 69(4):1246-53. PubMed ID: 17967314
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anticancer drug candidate CBL0137, which inhibits histone chaperone FACT, is efficacious in preclinical orthotopic models of temozolomide-responsive and -resistant glioblastoma.
    Barone TA; Burkhart CA; Safina A; Haderski G; Gurova KV; Purmal AA; Gudkov AV; Plunkett RJ
    Neuro Oncol; 2017 Feb; 19(2):186-196. PubMed ID: 27370399
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Increased cure rate of glioblastoma using concurrent therapy with radiotherapy and arsenic trioxide.
    Ning S; Knox SJ
    Int J Radiat Oncol Biol Phys; 2004 Sep; 60(1):197-203. PubMed ID: 15337556
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Radiosensitivity enhancement of human hepatocellular carcinoma cell line SMMC-7721 by sorafenib through the MEK/ERK signal pathway.
    Dai XF; Ding J; Zhang RG; Ren JH; Ma CM; Wu G
    Int J Radiat Biol; 2013 Sep; 89(9):724-31. PubMed ID: 23682582
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Iodide- and glucose-handling gene expression regulated by sorafenib or cabozantinib in papillary thyroid cancer.
    Ruan M; Liu M; Dong Q; Chen L
    J Clin Endocrinol Metab; 2015 May; 100(5):1771-9. PubMed ID: 25768669
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.